CCL

Összesen 1 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM005636
Első szerző:Massie, Barry M.
Cím:Irbesartan in patients with heart failure and preserved ejection fraction / Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., Ptaszynska, A., The I-PRESERVE Investigators
Dátum:2008
ISSN:1533-4406 (Electronic)
Megjegyzések:Approximately 50% of patients with heart failure have a left ventricular ejection fraction of at least 45%, but no therapies have been shown to improve the outcome of these patients. Therefore, we studied the effects of irbesartan in patients with this syndrome. METHODS: We enrolled 4128 patients who were at least 60 years of age and had New York Heart Association class II, III, or IV heart failure and an ejection fraction of at least 45% and randomly assigned them to receive 300 mg of irbesartan or placebo per day. The primary composite outcome was death from any cause or hospitalization for a cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death from heart failure or hospitalization for heart failure, death from any cause and from cardiovascular causes, and quality of life. RESULTS: During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval [CI], 0.86 to 1.05; P=0.35). Overall rates of death were 52.6 and 52.3 per 1000 patient-years, respectively (hazard ratio, 1.00; 95% CI, 0.88 to 1.14; P=0.98). Rates of hospitalization for cardiovascular causes that contributed to the primary outcome were 70.6 and 74.3 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% CI, 0.85 to 1.08; P=0.44). There were no significant differences in the other prespecified outcomes. CONCLUSIONS: Irbesartan did not improve the outcomes of patients with heart failure and a preserved left ventricular ejection fraction.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Adrenergic beta-Antagonists/therapeutic use
Aged
Angiotensin II Type 1 Receptor Blockers/adverse effects/ therapeutic use
Angiotensin-Converting Enzyme Inhibitors/therapeutic use
Biphenyl Compounds/adverse effects/ therapeutic use
Cardiovascular Diseases/epidemiology/mortality
Drug Therapy, Combination
Female
Follow-Up Studies
Heart Failure/ drug therapy/mortality/physiopathology
Hospitalization/statistics & numerical data
Humans
Kaplan-Meiers Estimate
Male
Middle Aged
Proportional Hazards Models
Quality of Life
Stroke Volume
Tetrazoles/adverse effects/ therapeutic use
Treatment Failure
Megjelenés:The New England Journal of Medicine. - 359 : 23 (2008), p. 2456-2467. -
További szerzők:Carson, Peter E. McMurray, John J. Komajda, Michel McKelvie, Robert Zile, Michael R. Anderson, Susan Donovan, Mark Iverson, Erik Staiger, Christoph Ptaszynska, Agata Édes István (1952-) (kardiológus) The I-PRESERVE Investigators
Internet cím:DOI
elektronikus változat
Borító:
Rekordok letöltése1